Glaucoma in Adults-Screening, Diagnosis, and Management: A Review.

Importance Glaucoma is the most common cause of irreversible blindness worldwide. Many patients with glaucoma are asymptomatic early in the disease course. Primary care clinicians should know which patients to refer to an eye care professional for a complete eye examination to check for signs of glaucoma and to determine what systemic conditions or medications can increase a patient's risk of glaucoma. Open-angle and narrow-angle forms of glaucoma are reviewed, including a description of the pathophysiology, risk factors, screening, disease monitoring, and treatment options. Observations Glaucoma is a chronic progressive optic neuropathy, characterized by damage to the optic nerve and retinal nerve fiber layer, that can lead to permanent loss of peripheral or central vision. Intraocular pressure is the only known modifiable risk factor. Other important risk factors include older age, nonwhite race, and a family history of glaucoma. Several systemic medical conditions and medications including corticosteroids, anticholinergics, certain antidepressants, and topiramate may predispose patients to glaucoma. There are 2 broad categories of glaucoma, open-angle and angle-closure glaucoma. Diagnostic testing to assess for glaucoma and to monitor for disease progression includes measurement of intraocular pressure, perimetry, and optical coherence tomography. Treatment of glaucoma involves lowering intraocular pressure. This can be achieved with various classes of glaucoma medications as well as laser and incisional surgical procedures. Conclusions and Relevance Vision loss from glaucoma can be minimized by recognizing systemic conditions and medications that increase a patient's risk of glaucoma and referring high-risk patients for a complete ophthalmologic examination. Clinicians should ensure that patients remain adherent with taking glaucoma medications and should monitor for adverse events from medical or surgical interventions used to treat glaucoma.

[1]  T. Peto,et al.  Glaucoma in the Northern Ireland Cohort for the Longitudinal Study of Ageing (NICOLA): cohort profile, prevalence, awareness and associations , 2020, British Journal of Ophthalmology.

[2]  B. Francis,et al.  American Glaucoma Society Position Paper: Microinvasive Glaucoma Surgery. , 2020, Ophthalmology. Glaucoma.

[3]  Jullia A. Rosdahl,et al.  Prospective Studies of Minimally Invasive Glaucoma Surgeries: Systematic Review and Quality Assessment , 2020, Clinical ophthalmology.

[4]  M. Coote,et al.  24-Month Phase I/II Clinical Trial of Bimatoprost Sustained-Release Implant (Bimatoprost SR) in Glaucoma Patients , 2019, Drugs.

[5]  Gian-Gabriel P. Garcia,et al.  Accuracy of Kalman Filtering in Forecasting Visual Field and Intraocular Pressure Trajectory in Patients With Ocular Hypertension. , 2019, JAMA ophthalmology.

[6]  Michael G. Anderson,et al.  Association of Genetic Variants With Primary Open-Angle Glaucoma Among Individuals With African Ancestry. , 2019, JAMA.

[7]  J. Wiggs,et al.  Clinical implications of recent advances in primary open-angle glaucoma genetics , 2019, Eye.

[8]  J. Fingert,et al.  Mendelian genes in primary open angle glaucoma. , 2019, Experimental eye research.

[9]  A. Robin,et al.  Medication adherence in patients with ocular hypertension or glaucoma , 2019, Expert Review of Ophthalmology.

[10]  C. Lindén,et al.  Efficacy and safety of transscleral cyclophotocoagulation in Swedish glaucoma patients , 2019, Acta ophthalmologica.

[11]  Tin Aung,et al.  Laser peripheral iridotomy for the prevention of angle closure: a single-centre, randomised controlled trial , 2019, The Lancet.

[12]  C. Bunce,et al.  Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial , 2019, The Lancet.

[13]  Gian-Gabriel P. Garcia,et al.  Using Kalman Filtering to Forecast Disease Trajectory for Patients With Normal Tension Glaucoma. , 2019, American journal of ophthalmology.

[14]  Michael V. Boland,et al.  Artificial intelligence in glaucoma , 2019, Current opinion in ophthalmology.

[15]  Tin Aung,et al.  A Schlemm Canal Microstent for Intraocular Pressure Reduction in Primary Open-Angle Glaucoma and Cataract: The HORIZON Study. , 2019, Ophthalmology.

[16]  Peter J. Bex,et al.  An Artificial Intelligence Approach to Detect Visual Field Progression in Glaucoma Based on Spatial Pattern Analysis , 2019, Investigative ophthalmology & visual science.

[17]  K. Resnicow,et al.  Personalized behavior change program for glaucoma patients with poor adherence: a pilot interventional cohort study with a pre-post design , 2018, Pilot and Feasibility Studies.

[18]  R. Weinreb,et al.  New Recommendations for the Treatment of Systemic Hypertension and their Potential Implications for Glaucoma Management. , 2018, Journal of glaucoma.

[19]  Geraint Rees,et al.  Association of Retinal Nerve Fiber Layer Thinning With Current and Future Cognitive Decline: A Study Using Optical Coherence Tomography , 2018, JAMA neurology.

[20]  W. Feuer,et al.  Treatment Outcomes in the Primary Tube Versus Trabeculectomy Study after 1 Year of Follow-up. , 2018, Ophthalmology.

[21]  Yeunjoo E. Song,et al.  Genome-wide analyses identify 68 new loci associated with intraocular pressure and improve risk prediction for primary open-angle glaucoma , 2018, Nature Genetics.

[22]  Philip P. Chen,et al.  Laser Peripheral Iridotomy in Primary Angle Closure: A Report by the American Academy of Ophthalmology. , 2018, Ophthalmology.

[23]  Pooyan Kazemian,et al.  Personalized Prediction of Glaucoma Progression Under Different Target Intraocular Pressure Levels Using Filtered Forecasting Methods. , 2017, Ophthalmology.

[24]  V. Sheffield,et al.  CRISPR-Cas9–based treatment of myocilin-associated glaucoma , 2017, Proceedings of the National Academy of Sciences.

[25]  N. Radcliffe,et al.  Combined endocyclophotocoagulation and phacoemulsification in the management of moderate glaucoma. , 2017, Survey of ophthalmology.

[26]  Gretchen A. Stevens,et al.  Magnitude, temporal trends, and projections of the global prevalence of blindness and distance and near vision impairment: a systematic review and meta-analysis. , 2017, The Lancet. Global health.

[27]  Hoifung Poon,et al.  Classification of common human diseases derived from shared genetic and environmental determinants , 2017, Nature Genetics.

[28]  A. Aref,et al.  A Review of Selective Laser Trabeculoplasty: Recent Findings and Current Perspectives , 2017, Ophthalmology and Therapy.

[29]  D. Mackey,et al.  Myocilin Predictive Genetic Testing for Primary Open-Angle Glaucoma Leads to Early Identification of At-Risk Individuals. , 2017, Ophthalmology.

[30]  Adriana I. Iglesias,et al.  New insights into the genetics of primary open-angle glaucoma based on meta-analyses of intraocular pressure and optic disc characteristics , 2017, Human molecular genetics.

[31]  M. Kass,et al.  Glaucoma Risk Alleles in the Ocular Hypertension Treatment Study. , 2016, Ophthalmology.

[32]  Augusto Azuara-Blanco,et al.  Effectiveness of early lens extraction for the treatment of primary angle-closure glaucoma (EAGLE): a randomised controlled trial , 2016, The Lancet.

[33]  R. Hogg,et al.  The Effect of Statins on Intraocular Pressure and on the Incidence and Progression of Glaucoma: A Systematic Review and Meta-Analysis. , 2016, Investigative ophthalmology & visual science.

[34]  M. Dinç,et al.  Effects of Use of a Continuous Positive Airway Pressure Device on Glaucoma , 2015, Medical science monitor : international medical journal of experimental and clinical research.

[35]  Tien Yin Wong,et al.  Prevalence, Risk Factors, and Visual Features of Undiagnosed Glaucoma: The Singapore Epidemiology of Eye Diseases Study. , 2015, JAMA ophthalmology.

[36]  A. Coleman,et al.  Burden of undetected and untreated glaucoma in the United States. , 2014, American journal of ophthalmology.

[37]  Ching-Yu Cheng,et al.  Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. , 2014, Ophthalmology.

[38]  F. Medeiros,et al.  The pathophysiology and treatment of glaucoma: a review. , 2014, JAMA.

[39]  P. Barberger‐Gateau,et al.  Is there a link between open‐angle glaucoma and dementia? , 2013, Annals of neurology.

[40]  D. Garway-Heath,et al.  How does glaucoma look?: patient perception of visual field loss. , 2013, Ophthalmology.

[41]  D. Simel,et al.  Do findings on routine examination identify patients at risk for primary open-angle glaucoma? The rational clinical examination systematic review. , 2013, JAMA.

[42]  Michael V. Boland,et al.  Comparative Effectiveness of Treatments for Open-Angle Glaucoma: A Systematic Review for the U.S. Preventive Services Task Force , 2013, Annals of Internal Medicine.

[43]  B. Nan,et al.  The relationship between statin use and open-angle glaucoma. , 2012, Ophthalmology.

[44]  W. Feuer,et al.  Postoperative complications in the Tube Versus Trabeculectomy (TVT) study during five years of follow-up. , 2012, American journal of ophthalmology.

[45]  J. Stein,et al.  Cost-effectiveness of medications compared with laser trabeculoplasty in patients with newly diagnosed open-angle glaucoma. , 2012, Archives of ophthalmology.

[46]  Denise S. Kim,et al.  Differences in rates of glaucoma among Asian Americans and other racial groups, and among various Asian ethnic groups. , 2011, Ophthalmology.

[47]  S. Azen,et al.  Blood pressure, perfusion pressure, and open-angle glaucoma: the Los Angeles Latino Eye Study. , 2010, Investigative ophthalmology & visual science.

[48]  S. Gedde,et al.  Review of results from the Tube Versus Trabeculectomy Study , 2010, Current opinion in ophthalmology.

[49]  H. Jampel American glaucoma society position statement: marijuana and the treatment of glaucoma. , 2010, Journal of glaucoma.

[50]  Brenda W Gillespie,et al.  Visual field progression in the Collaborative Initial Glaucoma Treatment Study the impact of treatment and other baseline factors. , 2009, Ophthalmology.

[51]  P. Foster,et al.  The utility of symptoms in identification of primary angle-closure in a high-risk population. , 2008, Ophthalmology.

[52]  H. Quigley,et al.  Adherence and persistence with glaucoma therapy. , 2008, Survey of ophthalmology.

[53]  A. Coleman,et al.  Factors associated with undiagnosed open-angle glaucoma: the Thessaloniki Eye Study. , 2008, American journal of ophthalmology.

[54]  M. C. Leske,et al.  Predictors of long-term progression in the early manifest glaucoma trial. , 2007, Ophthalmology.

[55]  J. Stein,et al.  Mechanisms of action and efficacy of argon laser trabeculoplasty and selective laser trabeculoplasty , 2007, Current opinion in ophthalmology.

[56]  A. Khawaja,et al.  Drops and falls. , 2006, Age and ageing.

[57]  L. Zangwill,et al.  Primary open-angle glaucoma in blacks: a review. , 2003, Survey of ophthalmology.

[58]  Douglas R. Anderson,et al.  Collaborative Normal Tension Glaucoma Study , 2003, Current opinion in ophthalmology.

[59]  M. C. Leske,et al.  Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. , 2002, Archives of ophthalmology.

[60]  E. Stefánsson,et al.  The impact of ocular blood flow in glaucoma , 2002, Progress in Retinal and Eye Research.

[61]  E. E. Hartmann,et al.  The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. , 2002, Archives of ophthalmology.

[62]  R. Klein,et al.  The prevalence of glaucoma in a population-based study of Hispanic subjects: Proyecto VER. , 2001, Archives of ophthalmology.

[63]  P. Lichter,et al.  Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. , 2001, Ophthalmology.

[64]  B. Prum,et al.  The advanced glaucoma intervention study (AGIS): 7. the relationship between control of intraocular pressure and visual field deterioration , 2000 .

[65]  M. C. Leske,et al.  Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. , 1999, American journal of ophthalmology.

[66]  A. Hofman,et al.  Genetic risk of primary open-angle glaucoma. Population-based familial aggregation study. , 1998, Archives of ophthalmology.

[67]  J. Javitt,et al.  Undertreatment of glaucoma among black Americans. , 1991, The New England journal of medicine.

[68]  A. Sommer,et al.  Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans. The Baltimore Eye Survey. , 1991, Archives of ophthalmology.

[69]  D. Minckler,et al.  Glaucoma , 2018, Methods in Molecular Biology.

[70]  C. R. Ethier,et al.  Biomechanical aspects of axonal damage in glaucoma: A brief review. , 2017, Experimental eye research.

[71]  S. Mansberger,et al.  Primary Open-Angle Glaucoma Preferred Practice Pattern(®) Guidelines. , 2016, Ophthalmology.

[72]  D. Hodge,et al.  Long-term trends in glaucoma-related blindness in Olmsted County, Minnesota. , 2014, Ophthalmology.

[73]  Pradeep Y Ramulu,et al.  Difficulty with out-loud and silent reading in glaucoma. , 2013, Investigative ophthalmology & visual science.

[74]  Richard A. Russell,et al.  The United Kingdom Glaucoma Treatment Study: a multicenter, randomized, placebo-controlled clinical trial: design and methodology. , 2013, Ophthalmology.

[75]  M. B. Shields,et al.  Glaucoma and systemic diseases. , 2010, Survey of ophthalmology.

[76]  Frederick W. Fraunfelder,et al.  Topiramate-associated acute, bilateral, secondary angle-closure glaucoma. , 2004, Ophthalmology.